Consistent with this, the small molecule antagonist of Bcl-2, ABT-737, has been shown to re-sensitise some cancer cells to CTL-induced death, 16 suggesting that it may have adjuvant activity for cell-based cancer immunotherapy. It is not clear how ABT-737 re-sensitises cancer cells to CL or GraB or how to use ABT-737 most appropriately in future clinical trials that combine drug-and immune-based therapies. We have therefore investigated the synergy between ABT-737 and GraB, and show that (1) GraB generates a persistent pro-apoptotic signal to die in cancer cells that overexpress Bcl-2 that can be released by ABT-737 even if GraB activity is subsequently blocked; (2) this signal is transduced by tBid but is blocked by Bcl-2 upstream of Bax and Bak, and neutralising Bcl-2 with ABT-737 then results in rapid activation of Bax and Bak and MOMP; and (3) the pro-apoptotic signal generated by GraB and blocked by Bcl-2 is surprisingly long lived and MOMP can be triggered by adding ABT-737 as long as 20 h after Pfp/GraB. This defines a 'window of opportunity' when ABT-737 and GraB can jointly kill cancer cells that overexpress Bcl-2, which will be important for defining treatment regimens to use ABT-737 most effectively in combination with immunotherapy.
Results
GraB generates a persistent apoptotic signal that is rapidly released by ABT-737. As MOMP is the critical event in apoptosis that is regulated by Bcl-2 family members 12, 15, 17, 18 we first used immunofluorescence staining for cyt c to investigate whether ABT-737 could restore MOMP in HeLa-Bcl-2 cells treated with Pfp/GraB or NK. HeLa-Bcl-2 cells treated with NK cells or Pfp/GraB alone showed punctate staining typical of intact mitochondria. However, staining became diffuse in HeLa-Bcl-2 cells treated with GraB-or NK in the presence of ABT-737, indicating that cyt c release had occurred (Figures 1a and b) . Importantly, this effect was owing to restoration of the mitochondrial pathway, because the caspase-inhibitor zVAD-fmk was added in these assays to prevent any contribution of caspases directly activated by GraB. Consequently, ABT-737 did not restore apoptosis per se in these assays. To formally demonstrate that ABT-737 could restore GraBinduced apoptosis in the HeLa-Bcl-2 cells we used conditions that activate the mitochondrial pathway, but do not activate caspases directly. 7, 14, 18 As expected, Bcl-2 overexpressing cells were resistant to GraB-induced apoptosis under these conditions but apoptosis was restored by ABT-737 as determined by annexin V binding (Figure 1c) or release of 51 Cr from the targets cells (Figure 1d ). Death was restored using low concentrations of ABT-737 (Figure 1e ), but was not restored by an inactive enantiomer of ABT-737 that cannot neutralise Bcl-2 ( Figure 1c) or if the cells were pre-treated with compound 20 (C20), which specifically blocks the activity of human GraB (14) (Figure 1d) ; thereby showing strong synergy between both GraB and ABT-737 to kill the Bcl-2 overexpressing cells.
Interestingly, ABT-737 was fully effective in restoring GraBinduced death of HeLa-Bcl-2 cells in these assays even if it was added 1 h after Pfp/GraB as shown by equivalent 51 Cr release (Figure 1f ), or if GraB activity was blocked by adding C20 after 30 min (t ¼ 30 min) followed by ABT-737 after 1 h (Supplementary Figure 1) . This suggested that GraB rapidly generates a pro-apoptotic signal in Bcl-2 overexpressing cells (within 30 min) that is sustained for at least another 30 min even if GraB activity is blocked. This prompted us to investigate the nature of this pro-apoptotic signal. To investigate this we first used time-lapse microscopy to follow HeLa-Bcl-2 cells pre-treated with Pfp/GraB for 1 h followed by addition of ABT-737. Cyt c was located in the mitochondria of the Pfp/GraB-treated HeLa-Bcl-2 cells but rapidly translocated to the cytoplasm almost immediately after ABT-737 was added (within 15 min) and the cells subsequently showed classic signs of apoptosis including rounding and blebbing (Supplementary Movie 1). Similar experiments using flow cytometry to quantify cyt c release also revealed that ABT-737 triggered maximum cyt c release within 15 min in HeLa-Bcl-2 cells that had been pre-treated with Pfp/GraB for 1 h (Figure 2a ). Immunoblot analysis also showed that although caspases were partially cleaved in HeLa-Bcl-2 cells treated with Pfp/GraB after 1 h, consistent with previous studies, 15 caspase-3, -7 and -9 were fully processed to their active forms within 20 min of adding ABT-737 (Supplementary Figure 2 , long arrows). This confirmed MOMP was required for full caspase activation and that ABT-737 treatment replicated the death observed in cells expressing endogenous levels of Bcl-2. These experiments demonstrated that ABT-737 rapidly de-represses the anti-apoptotic effect of Bcl-2 to trigger cyt c release and caspase activation in a near-simultaneous manner in cells that had been pre-treated with Pfp/GraB.
The rapid release of cyt c by ABT-737 in these assays suggested that the mitochondria were 'primed' to initiate MOMP in these cells once Bcl-2 had been neutralised, and raised some important questions. The first was how long do the mitochondria of Bcl-2 overexpressing cells remain primed to release cyt c? This is important because NK disengage from their targets after they deliver GraB. Sensitivity of their targets to ABT-737 may therefore be limited. How long the GraB-treated cells remain sensitive to ABT-737 may therefore . Overall, these studies revealed that GraB generates a long but finite proapoptotic signal that defines a 'window of opportunity' during which the Bcl-2 overexpressing cells are sensitive to ABT-737 and that these cells are likely to respond to multiple rounds of combined therapy with NK and ABT-737.
Bcl-2 blocks the pro-apoptotic signal initiated by GraB by binding to tBid upstream of Bax translocation and Bax/Bak activation. The second question raised by our observations was: what is the nature of priming that persists in GraB-treated HeLa-Bcl-2 cells to render them sensitive to ABT-737, and is persistent proteolytic activity by GraB required to sustain this pressure throughout the 'window of opportunity'? The molecular mechanism of GraB-induced MOMP involves direct cleavage of Bid at Asp75 and migration of tBid to the mitochondria where it activates the multimeric pro-apoptotic Bcl-2 family members (Bax or Bak) to cause MOMP. 15, [19] [20] [21] [22] Consistent with this we have previously demonstrated that Bid cleavage occurs upstream of Bcl-2 during GraB-induced death and that murine embryonic fibroblasts from both Bid À / À and Bax
mice were resistant to GraB-induced death 18 (and data not shown). Bcl-2 has been shown to bind and block the active form of all three pro-apoptotic proteins via different mechanisms depending on the strength and nature of the stimulus applied. [22] [23] [24] [25] [26] [27] We therefore investigated the role of Bid, Bax and Bak in maintaining the pressure to die in Bcl-2 overexpressing cells.
As Bcl-2 overexpressing cells were primed to undergo MOMP once ABT-737 was added at 1 h (Figure 1f, Figure 2 ), the pro-apoptotic signal must be active in these cells at this time. We therefore tested whether Bid, Bax or Bak were converted to their active conformation within 1 h of treatment with GraB. As expected, control HeLa cells treated with Pfp/ GraB generated a large amount of tBid (GraB-cleaved (gc) tBid), which was largely localised in the mitochondrial pellet, and also produced smaller amounts of a slower-migrating form of tBid cleaved directly by caspases (caspase-cleaved . GctBid was also generated and was localised to the mitochondrial fraction of HeLa-Bcl-2 cells treated with Pfp/GraB, but cctBid was not observed as MOMP had not occurred. The presence of GraB-cleaved Bid (gctBid) at mitochondria in HeLa-Bcl-2 cells showed that the death signal had reached mitochondria in the absence of ABT-737 and gctBid accumulation at the mitochondria also provided a mechanism through which ABT-737 might potentially trigger rapid MOMP, even if GraB activity had ceased some time earlier.
We next examined whether Bcl-2 protects cells by sequestering gctBid or Bax/Bak that had been activated by gctBid, and whether ABT-737 liberated gctBid and/or activated Bax/Bak from Bcl-2 to induce MOMP. Bax is generally located in the cytoplasm and translocates to mitochondria to cause MOMP, whereas Bak is constitutively located at the mitochondria of healthy cells. Although the mechanism by which Bax and Bak promote MOMP remains to be fully elucidated, both molecules change conformation before oligomerising in the mitochondrial outer membrane. We therefore investigated the cellular location and conformational change of Bax and Bak in HeLa-Bcl-2 cells treated with Pfp/GraB in the presence and absence of ABT-737. As expected, Bak was located exclusively in the mitochondrial fractions of treated and untreated cells (Figure 3b) . Bax was also predominantly in the mitochondrial fraction of cells after treatment with Pfp/GraB and ABT-737 (Figure 3b) .
The conformational change in Bax exposes its N-terminus, which can then be detected with an antibody that binds specifically in this region (clone 6A7). Using flow cytometry, 460% of HeLa cells treated with Pfp/GraB alone were positive for the 6A7 epitope as were a similar proportion of HeLa-Bcl-2 cells treated with Pfp/GraB and ABT-737; background 6A7 binding occurred in the HeLa-Bcl-2 cells . ABT-737 (500 nM) was added to the cells indicated after 1 h and incubated for a further 30 min before they were fixed and stained for Bax and cyt c. Images were obtained using an Olympus FV1000 confocal microscope. Cells marked with an arrow indicate cells with active Bax and those with an asterix indicate cells without active Bax. (d) HeLa and HeLa-Bcl-2 cells were treated with Pfp (1 nM)/GraB (25 nM) for 1 h. ABT-737 (500 nM) was added for a further 30 min. Flow cytometry was used to detect Bax activation using an antibody specific for the conformational-active form of Bax (clone 6A7). Data are average ± S.D. of four independent experiments. (e) Conformation change of Bax (upper panels) and Bak (lower panels) was determined by immunoprecipitation with conformation-specific antibodies against Bax (6A7) or Bak (Ab-1) (as described in the Materials and Methods). Lysis in Triton X-100 (TX) was used as a positive control for conformational change of Bax and Bak. (Figure 3c ). This was confirmed by immunocytochemistry, which showed punctate Bax staining (cells with arrows) in HeLa-Bcl-2 cells treated with Pfp/GraB and ABT-737 indicating mitochondrial localisation, which contrasted with the faint diffuse staining when these cells were treated with Pfp/GraB alone (Figure 3d ). The converse was observed for cyt c, located predominantly in mitochondria of HeLa-Bcl-2 cells treated with Pfp/GraB (punctate staining), and only released into the cytoplasm when ABT-737 was added (diffuse staining). Finally, immunoprecipitation with 6A7 showed activated Bax in HeLa-Bcl-2 cells treated with Pfp/GraB after ABT-737 addition but only background levels before (Figure 3e) . Thus, Bax only became enriched at the mitochondria and acquired an active conformation if Bcl-2 was neutralised by ABT-737. With respect to Bak, immunoprecipitation with Ab-1 antibody showed Bak was activated in Pfp/GraB-treated HeLa cells or HeLa-Bcl-2 cells treated with Pfp/GraB and ABT-737, but not activated in HeLa-Bcl-2 cells treated with Pfp/GraB alone. Untreated cells lysed with Triton X-100 were used as a positive control to induce epitope exposure for both molecules. 28 We therefore concluded that Bak and Bax were maintained in their non-active conformations unless Bcl-2 was neutralised by ABT-737, and that the presence of gctBid must therefore be required to maintain the sensitivity of the GraBtreated cells to ABT-737.
To determine how Bcl-2 was acting, we used co-immunoprecipitation to determine whether gctBid, Bax and/or Bak was directly bound to Bcl-2. Bax did not co-precipitate with Bcl-2 following treatment with Pfp/GraB alone, but did following ABT-737 addition (Figure 4a ). Bak did not associate with Bcl-2 either before or after ABT-737 (data not shown), although this may merely reflect the reduced ability of Bak to bind to the Bcl-2 overexpressed in these cells. 24, 26 The observed Bax/Bcl-2 binding did not prevent translocation of Bax to the mitochondria or prevent MOMP as cyt c was still released in cells treated with Pfp/GraB and ABT-737. These data suggest that Bcl-2 does not block GraB by directly binding Bax (or Bak), and consequently that ABT-737 does not promote MOMP by displacing Bax or Bak from Bcl-2. In contrast, we found that gctBid did co-precipitate with Bcl-2 in cells treated with Pfp/GraB alone (Figure 4b ), so this binding may prevent gctBid from activating Bax or Bak. Although addition of ABT-737 killed these cells, it did not displace large amounts of gctBid from Bcl-2. Rather ABT-737 generated cctBid, which could also associate with Bcl-2. In dying cells, the overexpressed Bcl-2 could therefore bind gctBid, cctBid, activated Bax and presumably ABT-737, but not sufficiently well to block apoptosis.
Together, the data clearly show that the GraB signal involves direct Bid cleavage. This signal is transduced as far as mitochondria, but is held in check by Bcl-2 upstream of Bax/Bak activation. We note importantly that gctBid (but not cctBid, Bak or Bax) was bound to Bcl-2 before ABT-737 addition. A small amount of displaced gctBid may then activate Bax/Bak, but this requires confirmation.
GctBid persists in cells during the 'window of opportunity' for sensitivity to ABT-737. For gctBid to maintain the pressure to die in GraB-treated cells, it must persist throughout the 'window of opportunity' during which GraB-treated cells were sensitive to ABT-737. We therefore determined using immunoblot analysis that gctBid is present after an extended time (17-18 h) and confirmed that cyt c was released once ABT-737 was added at this time, even if the GraB is no longer active ( Figure 5 ). Pfp/GraB were added to HeLa and HeLa-Bcl-2 cells (t ¼ 0) and caspase activity was completely blocked with the inhibitor Q-VD-OPh. GraB inhibitor, C20, was added to HeLa cells at t ¼ 0 h to confirm that cleavage of Bid and loss of cyt c were completely blocked in HeLa cells under these conditions. To assess the need for on-going GraB activity in HeLa-Bcl-2 cells, the same concentration of C20 was added at t ¼ 2 h to block any further GraB-mediated Bid cleavage and ABT-737 addition was delayed for a further 15 h (t ¼ 17 h), as indicated. Finally, cells were fractionated 30 min later and assayed for the presence of gctBid and loss of cyt c from the mitochondrial fraction. Although the level of gctBid detected in the mitochondria was reduced in the Bcl-2 cells in which C20 was added (top panel, Reduced gctBid levels were detected in a similar experiment (Supplementary Figure 3) where the loss of mitochondrial cyt c was also associated with increased cyt c levels in the cytosol. Overall, we showed that GraB induces a long-lived (up to 20 h, Figure 2b and Figure 5 ) death signal that was held in check by Bcl-2 but could be de-repressed by ABT-737. The presence of gctBid at mitochondria many hours after GraB proteolysis had stopped suggesting that gctBid bound to Bcl-2 is the long-lived signal generated by GraB, which renders Bcl-2 overexpressing cells sensitive to ABT-737. After 24 h, the cells resumed their resistance to either stimulus (Pfp/GraB or ABT-737) alone, but remained sensitive to both stimuli in combination.
Discussion
ABT-737 is a small molecule antagonist of Bcl-2 being trialled alone or in combination with cytotoxic drugs. 29 Our previous studies showed that co-overexpression of Bcl-2 and XIAP confer resistance of cancer cells to NK-induced death 14 and this may explain why some patients do not respond or relapse following therapy. Our current study demonstrates that ABT-737 can restore the mitochondrial pathway in the target cells and validates the potential of ABT-737 to be effective in combination with cell-based immunotherapy. Although ABT-737 can only restore the mitochondria-dependent pathway, MOMP also causes release of Smac/DIABLO to overcome XIAP. ABT-737 is therefore likely to restore NK-induced apoptosis in cancer cells that co-overexpress Bcl-2 and XIAP ( Figure 6 ). Just as some viruses express caspase inhibitors that are not neutralised by Smac/DIABLO (e.g., CrmA), some cancer cells harbour defects that prevent them from executing mitochondria-independent pathways to apoptosis (e.g., MCF-7 breast cancer cells are deficient in caspase-3). 30 ABT-737 may not fully restore NK-induced apoptosis in these cells but Bax/Bak-mediated mitochondrial damage could still induce caspase-independent death. We therefore suggest that ABT-737 may be useful together with immunotherapy using CL to kill cancer cells, even those that harbour defects in caspase activation.
We showed that the pro-apoptotic signal generated by GraB is surprisingly long lived (up to 20 h) and that this signal depended on persistent gctBid even when GraB proteolytic activity had long been inhibited ( Figure 5, Supplementary  Figure 3 ). Importantly this suggests that timing of ABT-737 administration might be critical for the success of CTL/NK therapies. For example, delayed treatment with ABT-737, possibly 12-16 h after delivery of the NK cells, is likely to generate a large pool of cancer cells 'primed' for death and therefore sensitive to ABT-737. Further, NK can persist for many days in the tumour environment and a single killer cell can encounter multiple targets in succession. Therefore, sequential doses of ABT-737 12-16 h apart may be more effective than a single-dose delivered at the same time as immunotherapy. We also showed that target cells that survive ABT-737 following the initial treatment with Pfp/GraB are still sensitive to subsequent treatments with Pfp/GraB and ABT-737 (Figure 2c ). Strategies that prolong the life of gctBid may also be worth exploring as degradation of Figure 6 Restoration of cell death by ABT-737 in cancer cells that overexpress Bcl-2 and caspase activity is blocked. GraB can activate a mitochondria-dependent pathway to cell death by cleaving Bid (left), which triggers MOMP. This pathway can be blocked by overexpression of Bcl-2. GraB can also trigger apoptosis by cleaving caspases directly (right) and this pathway can be blocked by overexpression of caspase inhibitors, such as XIAP. Cell death can therefore be achieved by the complementary pathway if only one pathway is blocked. In cases where both pathways are blocked, neutralising Bcl-2 with ABT-737 is sufficient to restore the mitochondrial pathway. This results in apoptosis by activation of caspases, which can be achieved directly via cyt c or indirectly by Smac/HtrA2 that can neutralise some caspase inhibitors. MOMP can also cause caspase-independent cell death as a consequence of mitochondrial damage. Restoration of GraB-induced MOMP by neutralising Bcl-2 will therefore cause death of the cell even if caspase activity cannot be restored ABT-737 is an adjuvant for NK cells VR Sutton et al tBid is a control element in many apoptotic pathways and stabilisation of tBid, or proteosome inhibition can greatly amplify apoptosis. 31 In addition to understanding the therapeutic potential of ABT-737 during cell-based immunotherapy our study elucidates how ABT-737 synergises with GraB to restore the mitochondrial death pathway. We found that gctBid translocated to mitochondria, but is bound to and held in check by Bcl-2 upstream of Bax/Bak activation. This block was rapidly neutralised by ABT-737 resulting in MOMP within 15 min. Interestingly, substantial amounts of gctBid remained bound to Bcl-2 after addition of ABT-737 even when cells were clearly destined to die. However, our data suggest that only partial release of gctBid (undetectable by immunoblot) from Bcl-2 may be required to activate Bax/Bak, a rapid and stochastic process that has been notoriously difficult to monitor, and the subject of intense study. 32 It is therefore likely that gctBid reduces the capacity of Bcl-2 to retain cell viability, as has been shown for cctBid 33, 34 and that Bax and Bak only become involved downstream of the gctBid/Bcl-2 interaction.
Our findings are consistent with a previous study that used plasmid transfection to deliver different levels of tBid, which mimicked cctBid. Cells primed to die with lower levels of tBid underwent MOMP faster (0-20 min) than cells with higher levels of tBid (40-120 min) following ABT-737 addition. 27 This model predicted that Bcl-2 blocked lower levels of tBid by a mechanism designated mode 1, but higher levels of tBid activated Bax and Bak, blocked by a different mechanism designated mode 2. Bcl-2 appears to block GraB-induced death by mode 1 in our model (direct antagonism of gctBid) as the signal was rapidly released by ABT-737 (o20 min) and did not involve prior activation of Bax or Bak. This questions whether mode 2 inhibition can be achieved when Bid is activated under physiological conditions. Our model, which is more physiological and therapeutically relevant, should be useful for future studies aiming to unravel the complex sets of interactions between pro-and anti-apoptotic Bcl-2 family members ultimately leading to MOMP, and thereby influence drug design to restore the mitochondrial pathway in cancer cells where MOMP is blocked.
